Each of this year’s Specialized Center of Research (SCOR) recipients will receive $1.25 million per year for five years, a total of $6.25 million. In addition, the society is renewing two existing grants for five more years.
The SCOR program brings together a cluster of at least three independent research teams working in complementary areas, each focused on the discovery of new approaches in therapies for patients with leukemia, lymphoma or myeloma.
The program encourages scientists from different disciplines to collaborate in the hopes of developing novel treatments. Awards go to those groups that best demonstrate outstanding scientific promise and the synergy that will occur from their combined efforts.
“The four SCOR grant recipients selected this year have assembled teams who are pursing new targets for therapy that have a high probability of leading to new vaccines and medicines to treat lymphoma and leukemia,” said Dr Marshall Lichtman, the society’s executive vice president, Research & Medical Programs.